Blinatumomab Improves Survival in Acute Lymphoblastic Leukemia
Two phase 3 studies evaluating blinatumomab (Blincyto, Amgen) in B-cell acute lymphoblastic leukemia (ALL) showed positive results for treatment benefit, Amgen reported. According to the press release, the 20120215 study met its primary endpoint of event-free survival for blinatumomab compared with conventional chemotherapy in pediatric patients with high-risk, B-cell ALL at first relapse. Additionally, the Children’s Oncology Group AALL1331 trial showed a strong trend toward improved disease-free survival and improved overall survival, markedly lower toxicity, and better minimal residual disease clearance for blinatumomab compared with chemotherapy, Pharmacy Times reports.
সম্পূর্ণ আর্টিকেলটি পড়ুন
We use cookies to ensure you get the best experience on our website.